IGG subclass variation of a monoclonal antibody binding to human Fc-gamma receptors

American Journal of Biochemistry and Biotechnology

Volumn 9, Issue 3, 2013, Pages 206-218

  Patel, Rekha ^a   Johnson, Krista K ^a   Andrien, Bruce A ^a   Tamburini, Paul P ^a  

^a ALEXION PHARMACEUTICALS   (United States)

Author keywords

Affinity; ELISA; FC gamma receptors; IgG subclass; Monoclonal antibodies; Surface Plasmon Resonance (SPR)

Indexed keywords

AFFINITY; ELISA; FC-GAMMA RECEPTORS; HUMAN PROTEINS; HUMANIZED ANTIBODY; HUMANIZED MONOCLONAL ANTIBODY; IGG SUBCLASS; VARIABLE REGIONS;

ANTIGENS; MONOCLONAL ANTIBODIES; PLASMONS;

SURFACE PLASMON RESONANCE;

FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IIIA; FC RECEPTOR IIIB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGENIC VARIATION; ARTICLE; ELECTROSPRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISOELECTRIC FOCUSING; SURFACE PLASMON RESONANCE;

EID: 84879312093     PISSN: 15533468     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajbbsp.2013.206.218     Document Type: Article

References (32)

1. Allen, J.M. and B. Seed, 1989. Isolation and expression of functional high-affinity Fc receptor complementary DNAs. Science, 243: 378-381. PMID: 2911749
2. Anderson, C.L., L. Shen, D.M. Eicher, M.D. Wewers and J.K. Gill, 1990. Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes. J. Expt. Med., 171: 1333-1345. DOI: 10.1084/jem.171.4.1333
3. Anegon, I., M.C. Cuturi, G. Trinchieri and B. Perussia, 1998. Interaction of FC receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Expt. Med., 167: 452-472. DOI: 10.1084/jem.167.2.452
4. Bruhns, P., B. Iannascoli, P. England, D.A. Mancardi and N. Fernandez et al., 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood, 113: 3716-3725. PMID: 19018092
5. Canfield, S.M. and S.L. Morrison, 1991. The binding affinity of human IgG for its high affinity FC receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J. Exp. Med., 173: 1483-1491.
6. Carter, P.J., 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol., 6: 343-357. DOI: 10.1038/nri1837
7. Chowdhury, P.S. and H. Wu, 2005. Tailor-made antibody therapeutics. Methods, 36: 11-24. DOI: 10.1016/j.ymeth.2005.01.002
8. Fanger, M.W., R.F. Graziano, L. Shen and P.M. Guyre, 1989. FC gamma R in cytotoxicity exerted by mononuclear cells. Chem. Immunol., 47: 214-253. PMID: 2532893
9. Fridman, W.H., 1993. Regulation of B-cell activation and antigen presentation by FC receptors. Curr. Opin. Immunol., 5: 355-360. DOI: 10.1016/0952-7915(93)90053-U
10. Gessner, J.E., H. Heiken, A. Tamm and R.E. Schmidt, 1998. The IgG Fc receptor family. Ann. Hematol., 76: 231-248. DOI: 10.1007/s002770050396
11. Guyre, C.A., M.E. Barreda, S.L. Swink and M.W. Fanger, 2001. Colocalization of FC gamma RI-targeted antigen with class I MHC: Implications for antigen processing. J. Immunol., 166: 2469-2478. PMID: 11160307
12. Horton, H.M., M.J. Bernett, E. Pong, M. Peipp and S. Karki et al., 2008. Potent in vitro and in vivo activity of an fc-engineered Anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res., 68: 8049-8057. DOI: 10.1158/0008-5472.CAN-08-2268
13. Hudson, P.J. and C. Souriau, 2003. Engineered antibodies. Nat. Med., 9: 129-134. DOI: 10.1038/nm0103-129
14. Karlsson, R., P.S. Katsamba, H. Nordin, E. Pol and D.G. Myszka, 2006. Analyzing a kinetic titration series using affinity biosensors. Anal. Biochem., 349: 136-147. PMID: 16337141
15. Maenaka, K., P.A.V.D. Merwe, D.I. Stuart, E.Y. Jones and P. Sondermann, 2001. The human low affinity Fcγ receptors IIa, IIb and III bind IgG with fast kinetics and distinct thermodynamic properties. J. Biol. Chem., 276: 44898-44904. DOI: 10.1074/jbc.M106819200
16. Natsume, A., R. Niwa and M. Satoh, 2009. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des. Dev. Ther., 3: 7-16.
17. Nimmerjahn, F. and J.V. Ravetch, 2005. Divergent immunoglobulin g subclass activity through selective fc receptor binding. Science, 310: 1510-1512. DOI: 10.1126/science.1122009
18. Nissim, A. and Y. Chernajovsky, 2008. Historical development of monoclonal antibody therapeutics. Therapeutic Antibodies, 181: 3-18. DOI: 10.1007/978-3-540-73259-4_1
19. Oganesyan, V., M.M. Damschroder, R.M. Woods, K.E. Cook and H. Wu et al., 2009. Structural Characterization of a human FC fragment engineered for extended serum half-life. Mol. Immunol., 46: 1750-1755.
20. Piggee, C., 2008. Therapeutic antibodies coming through the pipeline. Anal. Chem., 80: 2305-2310. DOI: 10.1021/ac086033v
21. Presta, L.G., R.L. Shields, A.K. Namenuk, K. Hong and Y.G. Meng, 2002. Engineering therapeutic antibodies for improved function. Biochem. Soc. Trans., 30: 487-490. DOI: 10.1042/BST0300487
22. Salfield, J.G., 2007. Isotype selection in antibody engineering. Nat. Biotech., 25: 1369-1372. DOI: 10.1038/nbt1207-1369
23. Sautes, F.C., L. Cassard, S.J. Cohen and W.H. Fridman, 2003. FC gamma receptors: A magic link with the outside world. ASHI Q. Four. Q.
24. Shields, R.L, A.K. Namenuk, H. Kyu, Y.G. Meng and J. Rae et al., 2001. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem., 276: 6591-6604. DOI: 10.1074/jbc.M009483200
25. Sisto, M., S. Lisi, S. D'Amore and M. D'Amore, 2009. Autoantibodies, human Fcγ receptors and autoimmunity. J. Recep. Ligand Chann. Res., 2 45-57.
26. Sorge, N.M.V., W.L.V.D. Pol and J.G.J.V.D. Winkel, 2003. FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens, 61: 189-202. DOI: 10.1034/j.1399-0039.2003.00037.x
27. Stavenhagen, J.B., S. Gorlatov, N. Tuaillion, C.T. Rankin and H. Li et al., 2007. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res., 67: 8882-8890. DOI: 10.1158/0008-5472.CAN-07-0696
28. Stockwin, L.H. and S. Holmes, 2003. The role of therapeutic antibodies in drug discovery. Biochem. Soc. Trans., 31: 433-436.
29. Strome, S.E., E.A. Sausville and D. Mann, 2007. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist, 12: 1084-1095. DOI: 10.1634/theoncologist.12-9-1084
30. Wypych, J., M. Li, A. Guo, Z. Zhangans T. Martinez et al., 2008. Human IgG2 antibodies display disulfidemediated structural isoforms. J. Biol. Chem., 283: 16194-16205. DOI: 10.1074/jbc.M709987200
31. 19 antibody: Increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates. Blood, 113: 3735-3743. DOI: 10.1182/blood-2008-10-182048
32. Zhang, Q., G. Chen, X. Liu and Q. Qian, 2007. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res., 17: 89-99. DOI: 10.1038/sj.cr.7310143